Evidence types
Conference abstract articles covering early IBD findings presented at medical meetings before full publication. Research context emphasizes studies, trials, biomarkers, mechanisms, and emerging IBD science.
12 articles
Fibrostenotic Crohn’s disease (intestinal strictures from scar tissue) has few non-surgical treatment options. An investigational drug aimed at fibrosis could eventually offer a medical alternative to surgery if research...
TREMFYA (guselkumab) is an IL-23 inhibitor being studied for ulcerative colitis and Crohn's disease; new trial data could affect future treatment options. For people with IBD, drug-development news may indicate upcoming...
If metabolomic blood markers can reliably indicate IBD risk years before symptoms, researchers may better understand disease development and eventually design earlier detection or prevention strategies. For patients, the...
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original...
This is early-stage research about combining antibody targets (α4β7 and TL1A) for IBD; if validated in humans, combination biologics could offer improved effectiveness or dosing convenience.
If you have IBD or are at risk for colorectal disease, clinicians at the conference highlighted that these conditions are being seen more often and that treatment approaches have shifted toward personalized medicine and...
The article reports rising colorectal disease and IBD rates and describes modern shifts in treatment—topics that can affect screening, treatment options, and specialist care access for people with IBD or colorectal...
Cure8 found this source from eagletribune.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for...
This roundup highlights new IBD research and real-world care issues that could influence future diagnosis, monitoring, and access to treatments. Findings on financial barriers and gaps in treat-to-target monitoring may...
This signals new investigational IBD research focused on a novel immune pathway (TL1A/DR3) that could lead to future treatments. For people with Crohn’s/IBD, it’s an early-stage development to watch, but not an immediate...
Researchers and companies continue exploring new immune-targeted therapies for IBD. A new DR3-targeted antibody could become a future treatment direction if clinical studies show benefit and safety. This announcement...
